Konsyl Pharmaceutical is categorized under Business Services (Unclassified) in Fort Worth, TX and active since 2007.
Konsyl Pharmaceutical was established in 2007, and today employs 1 to 4, earning $10.000.000 to $19.9999.999 per year. This is a Business Services (Unclassified) business, which does work in the B2B market, and is classified as a Business Services (Unclassified), under code number 561499 by the NAICS.
If you are seeking more information, feel free to contact Judy Copelin at the company’s single location by writing to 4200 South Hulen St, Fort Worth, Texas TX 76109 or by phoning (817) 763-1464. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Konsyl Pharmaceutical |
| Contact Person: | Judy Copelin |
| Address: | 4200 South Hulen St, Fort Worth, Texas 76109 |
| Phone Number: | (817) 763-1464 |
| Annual Revenue (USD): | $10.000.000 to $19.9999.999 |
| Founded: | 2007 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Business Services (Unclassified) |
| SIC Code: | 7389 |
| NAICS Code: | 561499 |
| Share This Business: |
Konsyl Pharmaceutical was started in 2007 to provide professional Business Services (Unclassified) under the SIC code 7389 and NAICS code 561499. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $10.000.000 to $19.9999.999 per annum.
Feel free to contact Judy Copelin for inquiries that concern Konsyl Pharmaceutical by calling the company number (817) 763-1464, as your correspondence is most welcome. Additionally, the physical location of the single location of Konsyl Pharmaceutical can be found at the coordinates 32.687355,-97.392769 as well as the street address 4200 South Hulen St in Fort Worth, Texas 76109.
For its online presence, you may visit Konsyl Pharmaceutical’s website at and engage with its social media outlets through on Twitter and on Facebook.